AyuVis
AyuVis Research is developing a platform of immunotherapies to prevent and treat life-threatening diseases with no current, effective therapies. Their solutions are transformational because they are not hindered by drug resistance and do not cause immunosuppression. The company harnesses novel small molecules to modulate the body's immune response, aiming to address unmet medical needs in respiratory diseases, infections, and inflammatory conditions. They focus on diseases such as bronchopulmonary dysplasia, acute respiratory distress syndrome, and pneumonia, with a pipeline that includes innovative compounds like AVR-48 and AVR-25.
Industries
Nr. of Employees
small (1-50)
AyuVis
Patents
Products
Lead small-molecule immunotherapy candidate (chitohexaose-derived)
A chitohexaose-derived small-molecule immunotherapy designed to modulate macrophage activity via TLR4 to reduce hyperinflammation, promote tissue repair, and enhance microbial clearance; advanced through IND enabling studies and accepted by the FDA for Phase 1 clinical testing.
Discovery platform for innate-immune-targeting small molecules
Platform pipeline of rationally designed small-molecule analogs of chitohexaose aimed at modulating macrophage states to treat inflammation and infection across multiple indications.
AVR-48
A new generation immunotherapy drug developed by AyuVis that provides a well-balanced outcome with mild activation and controlled suppression of the immune system to effectively treat disease by controlling inflammation and infection.
AyuVis novel small molecule immune-modulating agent
A novel small molecule immune-modulating agent developed by AyuVis that enhances the body's ability to fight bacterial infection and inflammation when given via intravenous injection (IV), either alone or in combination with existing standard of care antibiotics. It has anti-inflammatory properties that differ from current steroids by not suppressing but synergistically enhancing the immune system.
AVR-25
A novel small molecule derived from chitin showing anti-inflammatory effects in lungs and potential therapeutic efficacy in experimental murine models of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).
small immunotherapy molecule for Retinopathy of Prematurity
A small immunotherapy molecule developed by AyuVis to prevent and treat Retinopathy of Prematurity (ROP) by modulating the immune system to reduce inflammation without altering essential eye growth factors.
Lead small-molecule immunotherapy candidate (chitohexaose-derived)
A chitohexaose-derived small-molecule immunotherapy designed to modulate macrophage activity via TLR4 to reduce hyperinflammation, promote tissue repair, and enhance microbial clearance; advanced through IND enabling studies and accepted by the FDA for Phase 1 clinical testing.
Discovery platform for innate-immune-targeting small molecules
Platform pipeline of rationally designed small-molecule analogs of chitohexaose aimed at modulating macrophage states to treat inflammation and infection across multiple indications.
AVR-48
A new generation immunotherapy drug developed by AyuVis that provides a well-balanced outcome with mild activation and controlled suppression of the immune system to effectively treat disease by controlling inflammation and infection.
AyuVis novel small molecule immune-modulating agent
A novel small molecule immune-modulating agent developed by AyuVis that enhances the body's ability to fight bacterial infection and inflammation when given via intravenous injection (IV), either alone or in combination with existing standard of care antibiotics. It has anti-inflammatory properties that differ from current steroids by not suppressing but synergistically enhancing the immune system.
AVR-25
A novel small molecule derived from chitin showing anti-inflammatory effects in lungs and potential therapeutic efficacy in experimental murine models of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).
small immunotherapy molecule for Retinopathy of Prematurity
A small immunotherapy molecule developed by AyuVis to prevent and treat Retinopathy of Prematurity (ROP) by modulating the immune system to reduce inflammation without altering essential eye growth factors.
Expertise Areas
- Immunomodulatory small-molecule discovery
- Preclinical efficacy in respiratory and sepsis models
- Medicinal chemistry and scalable process development
- CMC and GMP API readiness for clinical development
Key Technologies
- TLR4-targeted innate immune modulation
- Small-molecule medicinal chemistry
- Rational drug design and computational modeling
- Rodent models of ALI/ARDS, BPD, CLP sepsis, and bacterial lung infection
News & Updates
AyuVis received an NIH research grant from NHLBI to fund preparations and the initiation of a Phase 1 clinical trial for their immunotherapy drug AVR-48, which aims to treat inflammation and infection, especially in neonatal lung diseases.
AyuVis Research Selected for Virtual BLUE KNIGHT™ and Johnson & Johnson Innovation – JLABS Residency
AyuVis was selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS and BARDA, supporting the expansion of their drug development program and pursuit of additional funding.
Dr. Suchismita Acharya, Founder & CEO of AyuVis, was named a finalist for the Entrepreneur of the Year® 2023 Southwest Award, recognizing her leadership and innovative work in immunotherapy.
An article highlighting Dr. Acharya's professional development and her role at AyuVis, published by UNT Health Science Center.
An article discussing how local companies, including AyuVis, fund their innovation efforts through federal grants.
An article about AyuVis receiving a grant to support its pediatric drug development program.
AyuVis received an NIH research grant from NHLBI to fund preparations and the initiation of a Phase 1 clinical trial for their immunotherapy drug AVR-48, which aims to treat inflammation and infection, especially in neonatal lung diseases.
AyuVis Research Selected for Virtual BLUE KNIGHT™ and Johnson & Johnson Innovation – JLABS Residency
AyuVis was selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS and BARDA, supporting the expansion of their drug development program and pursuit of additional funding.
Dr. Suchismita Acharya, Founder & CEO of AyuVis, was named a finalist for the Entrepreneur of the Year® 2023 Southwest Award, recognizing her leadership and innovative work in immunotherapy.
An article highlighting Dr. Acharya's professional development and her role at AyuVis, published by UNT Health Science Center.
An article discussing how local companies, including AyuVis, fund their innovation efforts through federal grants.
An article about AyuVis receiving a grant to support its pediatric drug development program.